Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.5931
-0.0088 (-1.46%)
At close: Aug 10, 2026, 4:00 PM EDT
0.5862
-0.0069 (-1.16%)
After-hours: Aug 10, 2026, 6:20 PM EDT

Galmed Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
3.693.643.33.924.665.66
Research & Development
5.64.872.983.571327.22
Total Operating Expenses
9.298.516.287.4917.6532.88
Operating Income
-9.29-8.51-6.28-7.49-17.65-32.88
Total Non-Operating Income (Expense)
-3.18-3.28-2.27-0.58-0.220.41
Pretax Income
-12.47-11.79-8.55-8.07-17.87-32.47
Net Income
-12.47-11.79-8.55-8.07-17.87-32.47
Net Income to Common
-11.12-10.31-7.52-6.91-17.87-32.47
Net Income Growth
------
Shares Outstanding (Basic)
641000
Shares Outstanding (Diluted)
641000
Shares Change
348.01%363.17%303.31%65.23%2.22%15.58%
EPS (Basic)
-2.17-2.39-8.08-30.00-127.80-237.60
EPS (Diluted)
-2.17-2.39-8.08-30.00-127.80-237.60
EPS Growth
------
Free Cash Flow
-7.68-6.32-5.88-6.14-18.51-32.9
Free Cash Flow Growth
------
Free Cash Flow Per Share
-1.40-1.46-6.32-26.59-132.48-240.78
EBITDA
-9.29-8.51-6.2-7.46-17.62-32.84
EBIT
-9.29-8.51-6.28-7.49-17.65-32.88
SEC Filings: 10-K · 10-Q